Anson Funds Management’s Humacyte HUMA Stock Holding History

Anson Funds Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50,000	Closed	-$240K	–	180
2024 Q2	$240K	Hold	50,000	–	–	0.03%	139
2024 Q1	$156K	Buy	+50,000	New	+$168K	0.01%	131

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Anson Funds Management's HUMA Position: Q3 2024 in Review

Anson Funds Management sold out of Humacyte (HUMA) in Q3 2024, closing a stake of 50,000 shares — an estimated $240K sold.

Anson Funds Management first reported a position in HUMA in Q1 2024 and held it in 2 quarters. The position peaked at $240K in Q2 2024. 143 funds tracked by Wall St. Rank hold HUMA as of Q3 2024.

Anson Funds Management reported no remaining Humacyte position as of Q3 2024 after selling out during the quarter.
Anson Funds Management sold 50,000 Humacyte shares in Q3 2024, an estimated $240K.
Anson Funds Management first reported a position in Humacyte in Q1 2024 and held it in 2 quarters.
Anson Funds Management's Humacyte position peaked at $240K in Q2 2024.
143 funds tracked by Wall St. Rank held Humacyte as of Q3 2024.

Based on Anson Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.